

[Search Journal](#)[Subscribe](#)[Log Out](#)

- [Jobs](#)
- [Awards and Announcements](#)
- [Conferences](#)
- [Press Services](#)
- [General Info](#)
- [Free Sample](#)
- [Info for Authors](#)
- [Contact Us](#)

THE LANCET
Infectious Diseases

THE LANCET
Oncology

LANCET
Neurology Network

[Home](#) > [Search Journal](#) > [Simple](#) > [Results](#) > [Abstract](#)

Volume 354, Number 9186
09 October 1999

[Back to results](#) >>

Research letters

Olestra increases faecal excretion of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin

Alexandra Geusau, Erwin Tschachler, Michael Meixner, Steffen Sandermann, Olaf Pöpke, Christian Wolf, Eva Valic, Georg Stingl, Michael McLachlan

Two patients with chloracne had concentrations of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) of 144 000 and 26 000 pg/g blood lipids. Olestra, a non-digestible, lipophilic dietary fat substitute accelerated the patients' intestinal excretion of TCDD by eight to ten fold. This is sufficient to reduce the normally observed elimination half life of TCDD from about 7 years to 1-2 years.

Department of Dermatology, Division of immunology, Allergy and Infectious Diseases (DIAID) (A Geusau MD, E Tschachler MD, M Meixner MD, S Sandermann MD, G Stingl MD), **Department of Medicine, Division of Occupational Medicine** (C Wolf MD, E Valic MD), **University of Vienna Medical School, Austria; ERGO Forschungsgesellschaft, Hamburg, Germany** (O Pöpke MD); and **Baltic Sea Research Institute, D18112 Rostock, Germany** (M McLachlan MD)

Correspondence to: Dr M McLachlan (e-mail: michael.mclachlan@jo-warnemuende.de)

[▲ top](#)